Moreover, HEADWATERS has repurchased and canceled $5.0 million in aggregate principal amount of its 2.50% Convertible Subordinated Notes due 2014 for consideration of approximately $4.7 million, including accrued interest through the purchase date of approximately $0.05 million, pursuant to an open market transaction. After the closing of the note purchase, Headwaters has $58.6 million in aggregate principal amount of its 2.50% Notes remaining.
http://www.headwaters.com
Heidelberg Instruments announced order for an advanced DWL 2000 system with sophisticated Gray Scale Exposure capability from Heptagon. The System will be used for production of micro optical components for applications in smart phones, mobile devices, gaming consoles, telecoms equipment and supercomputers.
http://www.himt.de
HelioVolt announced successful completion of testing of the next series of high efficiency thin film solar modules. HelioVolt now offers a range of solar panels based on the company’s proprietary CIGS (Copper Indium Gallium Selenide) technology platform. The new series of high performance modules features HelioVolt’s frameless glass-glass construction and monolithic integration offering customers outstanding energy yield, cost, and reliability.
"Our unique technology and manufacturing capabilities allow HelioVolt to continue to rapidly expand our product portfolio. We are also pleased that our panels offer industry leading narrow power distributions to deliver higher system performance to our customers," said Dr. BJ Stanbery, HelioVolt’s founder and Chairman of the Board.
http://www.heliovolt.net
IBM (NYSE: IBM) has entered into a definitive agreement to acquire Texas Memory Systems (TMS), a leading developer of high-performance flash memory solutions. TMS is a privately held company based in Houston, Texas. Financial terms of the deal were not disclosed.
http://www.ramsan.com
llumina (NASDAQ: ILMN) launched its real-time PCR reagent portfolio, including a novel, probe-based chemistry for gene expression analysis called NuP- CRTM. In addition to the NuPCR Reagents, Illumina announced qPCR DNA Binding Dye (DBD) Assays for Gene Expression Analysis and qPCR High Resolution Melting (HRM) Assays for genotyping studies, providing researchers with a trio of high-quality, budget-friendly options in the qPCR reagent market. Moreover, Illumina announced its financial results for the second quarter of 2012. Revenue decrease 2% to $281 million ($287m in 2Q 2011); GAAP net income for the quarter was $23 million, or $0.18 per diluted share, compared to net income of $31 million, or $0.22 per diluted share, for the second quarter of 2011. The cash flow from operations was $96 million compared to cash flow from operations
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105